WHO obesity guidance SBP warns on slimming drugs

Aug 24

In a live Rio report and package, Anna Karina de Carvalho describes WHO's new child and adolescent obesity guidance, emphasizing family care, dietary and activity changes, specialist supervision and age restrictions for medicines or surgery. Latife Salomão Tyszler describes lifestyle changes as the first approach and medicines after unsuccessful interventions. The reporter says 170 million people aged 5–19 had obesity 'in Brazil'; this geographic attribution is what aired, rather than a verified national figure. The package then revisits an August 2026 Brazilian Society of Pediatrics warning about injectable obesity medicines: medical indications, growth and other adverse risks, pressure over appearance, and avoidance of cosmetic use without proper assessment. Adriane Cardoso stresses specialist and multidisciplinary follow-up. Neither guide establishes that all children should receive medicines.

The Brazilian Society of Pediatrics issues an August 2026 warning about inappropriate injectable obesity-medicine use in children and adolescents. TV Brasil's retrospective lists growth/development deficits, dehydration, muscle loss, pancreatitis and gallbladder risks, and describes susceptibility to appearance pressure and untrustworthy products. Specialists emphasize specific clinical indications, pediatric endocrinology and multidisciplinary supervision, rather than cosmetic weight loss.